0000899243-17-022447.txt : 20170922 0000899243-17-022447.hdr.sgml : 20170922 20170922173101 ACCESSION NUMBER: 0000899243-17-022447 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170914 FILED AS OF DATE: 20170922 DATE AS OF CHANGE: 20170922 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sirgo Mark A CENTRAL INDEX KEY: 0001301715 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31361 FILM NUMBER: 171098302 MAIL ADDRESS: STREET 1: C/O BIODELIVERY SCIENCES INTERNATIONAL STREET 2: 801 CORPORATE CENTER DRIVE -SUITE 210 CITY: RALEIGH STATE: NC ZIP: 27607 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIODELIVERY SCIENCES INTERNATIONAL INC CENTRAL INDEX KEY: 0001103021 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 352089858 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4131 PARKLAKE AVENUE STREET 2: SUITE 225 CITY: RALEIGH STATE: NC ZIP: 27612 BUSINESS PHONE: 919 582 9050 MAIL ADDRESS: STREET 1: 4131 PARKLAKE AVENUE STREET 2: SUITE 225 CITY: RALEIGH STATE: NC ZIP: 27612 FORMER COMPANY: FORMER CONFORMED NAME: MAS ACQUISITION XXIII CORP DATE OF NAME CHANGE: 20000111 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-09-14 0 0001103021 BIODELIVERY SCIENCES INTERNATIONAL INC BDSI 0001301715 Sirgo Mark A C/O BIODELIVERY SCIENCES INTL, INC., 4131 PARKLAKE AVENUE, SUITE 225 RALEIGH NC 27612 1 1 0 0 President and CEO Common Stock 2017-09-14 4 S 0 50000 2.95 D 1509262 D Common Stock 2017-09-15 4 M 0 45421 1.78 A 1554683 D Common Stock 2017-09-15 4 M 0 33026 1.96 A 1587709 D Common Stock 2017-09-15 4 S 0 54833 2.90 D 1532876 D Common Stock 2017-09-18 4 S 0 6000 2.85 D 1526876 D Common Stock 2017-09-19 4 M 0 13661 2.01 A 1540537 D Common Stock 2017-09-19 4 S 0 24516 2.75 D 1516022 D Common Stock 2017-09-20 4 M 0 25000 2.26 A 1541022 D Common Stock 2017-09-20 4 M 0 34265 2.43 A 1575286 D Common Stock 2017-09-20 4 S 0 65405 2.75 D 1509881 D Common Stock 2017-09-21 4 S 0 619 2.75 D 1509262 D Options 1.78 2017-09-15 4 M 0 45421 0.00 D 2013-02-09 2022-02-09 Common Stock 45421 0 D Options 1.96 2017-09-15 4 M 0 33026 0.00 D 2013-02-15 2022-02-15 Common Stock 33026 0 D Options 2.01 2017-09-19 4 M 0 13661 0.00 D 2009-07-24 2018-07-24 Common Stock 6902 0 D Options 2.26 2017-09-20 4 M 0 25000 0.00 D 2011-07-21 2020-07-21 Common Stock 25000 0 D Options 2.43 2017-09-20 4 M 0 34265 0.00 D 2011-07-21 2020-07-21 Common Stock 34265 0 D On September 14, 2017, the Reporting Person sold an aggregate of 50,000 shares of the Issuer's Common Stock at a weighted average price of $2.95 per share. The highest sale price for the Common Stock was $2.98 per share and the lowest sale price was $2.90 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The options exercised were acquired from September 15, 2017 to September 19, 2017. The options exercised were acquired from September 19, 2017 to September 20, 2017. The options exercised were acquired from September 20, 2017 to September 21, 2017. On September 20, 2017, the Reporting Person sold an aggregate of 65,405 shares of the Issuer's Common Stock at a weighted average price of $2.75 per share. The highest sale price for the Common Stock was $2.78 per share and the lowest sale price was $2.75 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The Form 4 was due on September 18, 2017 but filed on September 22, 2017 to accommodate multiple connected transactions over several days all on one concise Form 4. /s/ Mark A. Sirgo 2017-09-22